Using moxibustion to treat hemorrhagic cystitis after stem cell transplantation
Clinical Study of Moxibustion in the Treatment of Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation
This study is testing whether a traditional Chinese medicine technique called moxibustion can help patients with bleeding in the bladder after receiving stem cell transplants feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06241274 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of moxibustion, a traditional Chinese medicine technique, in treating patients who develop hemorrhagic cystitis following allogeneic hematopoietic stem cell transplantation. The study plans to enroll 60 patients who will receive daily moxibustion treatments for 14 days, alongside symptomatic supportive care. Researchers will assess the severity of hemorrhagic cystitis and pain scores through daily urine routine collections to evaluate treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-55 who have developed hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.
Not a fit: Patients who have broken or sensitized skin at the moxibustion site or those who have undergone reduced-intensity conditioning prior to transplantation may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a non-invasive treatment option for patients suffering from hemorrhagic cystitis after stem cell transplantation.
How similar studies have performed: While the use of moxibustion is a traditional practice, this specific application in treating hemorrhagic cystitis post-transplantation is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. patients were fully aware of the study, participated voluntarily, and signed the informed consent form; 2. Age: 18-55 years old; 3. patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation; Exclusion Criteria: 1. refusal to participate in this clinical study; 2. broken or sensitized skin corresponding to the moxibustion site; 3. allogeneic hematopoietic stem cell transplantationpatients pretreated with the Reduced-intensity conditioning.
Where this trial is running
Wuhan, Hubei
- Yi Zhang — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: Yi Zhang
- Email: zy188603@163.com
- Phone: +86 15639790587
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.